---
title: "Jaguar Health (JAGX) news: reverse split and convertible notes"
url: "https://aibio.space/companies/jaguar-health/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "JAGX reverse split, convertible notes and merger news: Jaguar Health completes 1-for-15 reverse split and removes old preferred series. Jaguar Health, Inc."
---

JAGX Jaguar Health, Inc. NASDAQ · United States

# Jaguar Health (JAGX) news JAGX reverse split, convertible notes and merger news

Company Updates · 2026-10-28

## [Jaguar Health adds six-fold stock plan increase ahead of November vote](https://aibio.space/news/jaguar-health-adds-six-fold-stock-plan-increase-ahead-november-vote/)

A proxy supplement filed after a stock dividend explains a six-fold increase in shares available under the 2014 Stock Incentive Plan, which stockholders vote on November 6, 2026.

## Latest Jaguar Health news

1. 2026-09-28 Financings [Jaguar Health issues 481,584 shares to cut Streeterville note by $3,400,000](https://aibio.space/news/jaguar-health-issues-481-584-shares-cut-streeterville-note-3-400-000/) Jaguar issued 481,584 shares to Streeterville Capital in exchange for a $3,400,000 cut to a note first sold in 2021. The company reported about 1,945,542 shares outstanding as of September 25, 2026.
2. 2026-09-21 Listings [Jaguar Health completes 1-for-15 reverse split and removes old preferred series](https://aibio.space/news/jaguar-health-completes-1-15-reverse-split-removes-old-preferred/) The company effected the reverse split on September 17, 2026, and filed a certificate removing the terms of fourteen older preferred stock series from its charter, leaving about 520,088 common shares outstanding.
3. 2026-09-15 Financings [Jaguar Health swaps note and preferred shares for common stock](https://aibio.space/news/jaguar-health-swaps-note-preferred-shares-common-stock/) Jaguar Health exchanged a convertible note and Series Q preferred shares for common stock in September 2026, and issued 535,000 common shares plus a pre-funded warrant to acquire the Napo Therapeutics shares of a minority holder.
4. 2026-08-19 Company Updates [Jaguar Health reports second quarter 2026 net loss of $12.7 million](https://aibio.space/news/jaguar-health-reports-second-quarter-2026-net-loss-12-7-million/) Net loss attributable to common stockholders was $12.7 million for the quarter ended June 30, 2026, as U.S. revenue from its two main prescription products now flows to licensee Future Pak under a January 2026 agreement.
5. 2026-06-17 Debt Financing [Jaguar Health amends Streeterville and Uptown royalty deals and extends a note to October](https://aibio.space/news/jaguar-health-amends-streeterville-uptown-royalty-deals-extends-note/) Jaguar Health's monthly royalty minimums of $750,000.00 now start October 1, 2026 under both royalty interests, and a Streeterville note matures October 1, 2026 instead of July 1. Streeterville also received common stock for Series Q preferred shares.
6. 2025-10-01 Financings [Jaguar Health agrees to sell shares and pre-funded warrants to Brown Stone at $1.56](https://aibio.space/news/jaguar-health-agrees-sell-shares-pre-funded-warrants-brown-stone-1-56/) Jaguar agreed to sell 161,583 shares and 479,442 pre-funded warrants at $1.56 to Brown Stone Capital Limited. Two days later it issued 286,532 shares to cut a royalty balance by $600,000.

## Jaguar Health at a glance

- **Ticker**: JAGX

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.8 million

### Related companies

- [MapLight Therapeutics](https://aibio.space/companies/maplight-therapeutics/) NASDAQ: MPLT
- [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) NASDAQ: TTRX
- [Harbor Diversified](https://aibio.space/companies/harbor-diversified/) OTC: HRBR
- [Perrigo Company](https://aibio.space/companies/perrigo/) NYSE: PRGO
- [AbbVie](https://aibio.space/companies/abbvie/) NYSE: ABBV
- [NextCure](https://aibio.space/companies/nextcure/) NASDAQ: NXTC
- [Damora Therapeutics](https://aibio.space/companies/damora-therapeutics/) NASDAQ: DMRA
- [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH

### Also on NASDAQ

- [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN
- [PDS Biotechnology](https://aibio.space/companies/pds-biotechnology/) PDSB
- [Nuwellis](https://aibio.space/companies/nuwellis/) NUWE
- [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) ACTU
- [Kodiak Sciences](https://aibio.space/companies/kodiak-sciences/) KOD
- [NextCure](https://aibio.space/companies/nextcure/) NXTC

## What Jaguar Health does

Jaguar Health, Inc., together with its family company Napo Pharmaceuticals, Inc., develops novel prescription drugs derived sustainably from plants for people with complicated gastrointestinal disease states. Napo's crofelemer 125 mg delayed-release tablet, Mytesi, is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. In January 2026, Napo entered a United States licensing agreement with an affiliate of privately held Future Pak, LLC, which became the exclusive marketer for Mytesi and for Canalevia-CA1, a crofelemer prescription drug for chemotherapy-induced diarrhea in dogs. Jaguar received $16 million of non-dilutive capital at closing, with an additional $2 million due after post-closing conditions, and may receive up to $20 million in milestone payments. Jaguar will continue to manufacture crofelemer for both products. Napo Therapeutics, S.p.A. is developing new therapies for orphan and rare GI conditions. Magdalena Biosciences, a joint venture with Filament Health Corp., is focused on plant-derived medicines for mental health indications. The OnTarget Phase 3 trial of crofelemer did not meet its primary endpoint for the prespecified analysis of all tumor types and all targeted therapies.

| Product or program | What it is | Stage |
|---|---|---|
| Mytesi | Crofelemer delayed-release tablet for noninfectious diarrhea in adults with HIV/AIDS | FDA-approved |
| Canalevia-CA1 | Crofelemer tablet for chemotherapy-induced diarrhea in dogs |  |
| Crofelemer (OnTarget study) | Diarrhea prophylaxis in solid tumor patients receiving targeted therapies | Phase 3; did not meet primary endpoint for all tumor types |
| Magdalena Biosciences program | Plant-derived prescription medicines for mental health indications |  |

Summarised from the company's [10-K filed Apr 7, 2026](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/jagx-20251231.htm).

## Jaguar Health annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$11.5 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) | [$11.7 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) |
| Research and development | [$25.0 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) | [$16.5 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) |
| Net income (loss) | [-$53.6 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) | [-$38.5 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) |
| Cash from operations | [-$23.7 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) | [-$29.4 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) |
| Cash and equivalents | [$968,000](https://www.sec.gov/Archives/edgar/data/1585608/000119312526356570/) | [$8.0 million](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.8 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Jaguar Health

Did Jaguar Health do a reverse stock split?

Our latest story on this, dated Sep 21, 2026: "Jaguar Health completes 1-for-15 reverse split and removes old preferred series". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jaguar-health-completes-1-15-reverse-split-removes-old-preferred/).

Has Jaguar Health sold convertible notes?

Our latest story on this, dated Sep 15, 2026: "Jaguar Health swaps note and preferred shares for common stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jaguar-health-swaps-note-preferred-shares-common-stock/).

Is Jaguar Health involved in a merger or acquisition?

Our latest story on this, dated Sep 15, 2026: "Jaguar Health swaps note and preferred shares for common stock". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jaguar-health-swaps-note-preferred-shares-common-stock/).

What is the ticker symbol of Jaguar Health?

Jaguar Health, Inc. trades under the ticker JAGX on NASDAQ.

Where is Jaguar Health listed?

Jaguar Health, Inc. is listed on NASDAQ.

What is the SEC CIK of Jaguar Health?

The SEC Central Index Key (CIK) for Jaguar Health, Inc. is 1585608. Its filings are on SEC EDGAR.

How many shares does Jaguar Health have outstanding?

171,350,166 shares as of 2018-05-15, per the cover page of its 10-Q filed 2018-05-15.

Which country or territory is Jaguar Health listed under?

Our directory records Jaguar Health, Inc. under United States.

What does Jaguar Health do?

Our directory classifies Jaguar Health, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Jaguar Health?

The ISIN recorded for Jaguar Health, Inc. is US47010C8543.

Does aibio.space cover Jaguar Health?

aibio.space lists Jaguar Health, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Jaguar Health incorporated?

SEC records list its state or country of incorporation as DE.

What does Jaguar Health develop?

Jaguar Health, Inc., together with its family company Napo Pharmaceuticals, Inc., develops novel prescription drugs derived sustainably from plants for people with complicated gastrointestinal disease states. Napo's crofelemer 125 mg delayed-release tablet, Mytesi, is FDA-approved for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

What is Mytesi from Jaguar Health?

Mytesi: Crofelemer delayed-release tablet for noninfectious diarrhea in adults with HIV/AIDS Stage: FDA-approved.

What is Canalevia-CA1 from Jaguar Health?

Canalevia-CA1: Crofelemer tablet for chemotherapy-induced diarrhea in dogs Stage: Not stated.

## Investor discussion: Jaguar Health

Members talk about Jaguar Health (JAGX). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Jaguar Health, newest first. Each line links the filing it comes from.

1. 2026-10-08 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526417938/d78419ddef14a.htm)
2. 2026-09-28 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526403356/d187815d8k.htm)
3. 2026-09-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526396752/d79729d8k.htm)
4. 2026-09-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526395715/d78419dpre14a.htm)
5. 2026-09-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526391415/d105876dex991.htm)
6. 2026-09-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526391682/d162139d8k.htm)
7. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526352657/d103809dnt10q.htm)
8. 2026-07-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526292677/d145900d8k.htm)
9. 2026-06-22 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/d27128dex991.htm)
10. 2026-06-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/d111863d8k.htm)
11. 2026-06-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526266770/d570985d8k.htm)
12. 2026-06-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526261910/d85703dex991.htm)
13. 2026-06-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526253506/d95782d8k.htm)
14. 2026-05-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526240645/d129501dex991.htm)
15. 2026-05-19 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526231083/d227929d8k.htm)
16. 2026-05-18 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526228773/jagx_nt_10-q_05.18.2026.htm)
17. 2026-05-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526202614/d46623d8k.htm)
18. 2026-04-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088dex991.htm)
19. 2026-04-21 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526165120/d10648dex991.htm)
20. 2026-04-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526149828/d145473d8k.htm)
21. 2026-04-07 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526144470/jagx-20251231.htm)
22. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526137948/d105764dnt10k.htm)
23. 2026-03-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526122184/d22104ddef14a.htm)
24. 2026-03-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526106355/d22104dpre14a.htm)
25. 2026-03-09 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526097700/d89977d8k.htm)
26. 2026-03-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526096565/d62332d8k.htm)
27. 2026-02-18 Distress Reported a bankruptcy filing. SEC Form 8-K (Items 3.03,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526056157/d70748dex991.htm)
28. 2026-01-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm)
29. 2025-12-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312525317693/jagx-20251212.htm)
30. 2025-12-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1585608/000119312525311294/jagx-ex99_1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:JAGX on TradingView](https://www.tradingview.com/symbols/NASDAQ-JAGX/).

## SEC filings and registration

- **SEC name**: Jaguar Health, Inc.

- **CIK**: 1585608

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: JAGX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 200 PINE STREET SUITE 400, SAN FRANCISCO, CA, 94104

- **Phone**: 415-371-8300

- **Shares outstanding**: 171,350,166 as of 2018-05-15 (10-Q filed 2018-05-15)

- **Former names**: Jaguar Animal Health, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [S-3](https://www.sec.gov/Archives/edgar/data/1585608/000119312526429100/d169519ds3.htm) filed 2026-10-22
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1585608/000119312526417938/d78419ddef14a.htm) filed 2026-10-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1585608/000119312526413233/d183888d8k.htm) filed 2026-10-05
- [8-K](https://www.sec.gov/Archives/edgar/data/1585608/000119312526403356/d187815d8k.htm) filed 2026-09-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1585608/000119312526401239/d130901d8k.htm) filed 2026-09-25
- [424B5](https://www.sec.gov/Archives/edgar/data/1585608/000119312526400348/d155719d424b5.htm) filed 2026-09-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1585608/000119312526400087/d161376d8k.htm) filed 2026-09-24
- [8-K](https://www.sec.gov/Archives/edgar/data/1585608/000119312526396752/d79729d8k.htm) filed 2026-09-21

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001585608), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Jaguar Health, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker JAGX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Jaguar Health, Inc.

- **Ticker**: JAGX

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US47010C8543

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-JAGX/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/jaguar-health/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jaguar Health (JAGX) news: reverse split and convertible notes", 2026-10-31, https://aibio.space/companies/jaguar-health/